$0.24+0.01 (+2.57%)
Mangoceuticals Inc. (MGRX) is a Misc Health and Biotechnology Services company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for MGRX, including 3 SEC filings, 3 insider trades and 1 press release or news item. The most recent was published Oct 9, 2026.
Price$0.24+0.01 (+2.57%)
06:15 PM06:30 PM
News · 26 weeks29+600%
2026-05-032026-10-25
Mix2590d
- SEC Filings11(44%)
- Other10(40%)
- Insider3(12%)
- Offering1(4%)
Latest news
25 items- SECSEC Form 8-K filed by Mangoceuticals Inc.8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form 424B5 filed by Mangoceuticals Inc.424B5 - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market CloseTransaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced the closing of a registered direct offering with a U.S.-based private investment firm, priced at a premium to the Company’s recent closing share price. Management believes the transaction reflects investor interest in the Company’s strategy and long-term opportun
- INSIDERSEC Form 4 filed by Mangoceuticals Inc.4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- INSIDERSEC Form 4 filed by Mangoceuticals Inc.4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- INSIDERSEC Form 4 filed by Mangoceuticals Inc.4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Mangoceuticals Inc.SCHEDULE 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)
- SECMangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECMangoceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form 10-Q filed by Mangoceuticals Inc.10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)
- SECSEC Form 425 filed by Mangoceuticals Inc.425 - MANGOCEUTICALS, INC. (0001938046) (Subject)
- PRNuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology AssetsThe acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.Mississauga, Ontario--(Newsfile Corp. - August 13, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announces that its wholly owned subsidiary, Nucl
- PRMangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology AssetsThe acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies. DALLAS, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced that its merger partner, Nuclea Energy, Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled,
- PRNuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing InfrastructureThe MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacityMississauga, Ontario--(Newsfile Corp. - August 6, 2026) - Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, today announced that it has signed a non-binding memorandum of understanding (the "MOU") with New Mining Co. ("New Mining"), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to evaluate the technical and structural feasibility of deploying Nuclea's modula
- PRMangoceuticals’ Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing InfrastructureMOU will assess the technical feasibility of integrating Nuclea’s modular reactor technology into New Mining’s data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Dallas, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced that its merger partner, Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, has signed a non-binding memorandum of understanding (the "MOU") with New Mining Co. ("New Mining"), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to
- PRNuclea Energy USA Inc. Announces MOU with Utah Office of Energy DevelopmentThe MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab to advance the Morpheus microreactor toward demonstration and deploymentSalt Lake City, Utah--(Newsfile Corp. - August 5, 2026) - Nuclea Energy USA Inc. ("Nuclea USA"), a wholly owned subsidiary of Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology developer, is pleased to publicly announce the signing of a memorandum of understanding (MOU) on June 2, 2026 with the State of Utah Office of Energy Development ("OED") to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab ("USREL") to advance the deployment of Nuclea's Morpheus Micro Reactor.The MOU marks an import
- PRMangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy DevelopmentThe MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor toward demonstration and deployment Dallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced that its merger partner’s wholly owned subsidiary, Nuclea Energy USA Inc. ("Nuclea USA"), has signed a memorandum of understanding (the "MOU") with the State of Utah Office of Energy Development ("OED") to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab ("USREL") to advance the
- SECSEC Form 425 filed by Mangoceuticals Inc.425 - MANGOCEUTICALS, INC. (0001938046) (Subject)
- SECMangoceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business CombinationDallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1, 2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US $1.00 per share for a minimum of 10 consecutive business days. Nasdaq granted the extension after determining that Mangoceuticals meets the continued listing requirement for market value of publicly held shares an
- SECSEC Form 425 filed by Mangoceuticals Inc.425 - MANGOCEUTICALS, INC. (0001938046) (Subject)
- PRNuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus MicroreactorTransaction positions Nuclea to fund the development and commercialization of its lead-cooled, factory-built microreactor as AI and data center growth drives a generational expansion in U.S. electricity demandMississauga, Ontario--(Newsfile Corp. - July 30, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announced that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals")."This agreement gives Nuclea a fast
- SECSEC Form 425 filed by Mangoceuticals Inc.425 - MANGOCEUTICALS, INC. (0001938046) (Subject)
- SECMangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
- PRMangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor TechnologyBusiness Combination Agreement to Bring Nuclea's Lead-Cooled Morpheus Microreactor to the Public Markets Amid Surging Power Demand from AI and Data Centers DALLAS, TEXAS, July 30, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") today announced that it has entered into a definitive business combination agreement (the "Agreement") with Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology company founded in August 2023 and headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor. Nuclea is advancing its Morpheus nuclear reactor from the current design stage through
MGRX FAQ
6 questionsWhat is the latest news on MGRX?
In the last 30 days Quantisnow tracked 8 wire items for MGRX: 3 SEC filings, 3 insider trades, 1 press release or news item and 1 offering. The most recent was published on October 9, 2026.Where does MGRX stock trade?
Mangoceuticals Inc. (MGRX) is listed on NASDAQ.What sector and industry is MGRX in?
Mangoceuticals Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did Mangoceuticals Inc. go public?
Mangoceuticals Inc. (MGRX) completed its IPO in 2023.What companies are similar to MGRX?
Notable peers in the same industry include FMS (Fresenius Medical Care AG), DVA (DaVita Inc.), SHC (Sotera Health Company), PGNY (Progyny Inc.), AGL (agilon health inc.). Compare MGRX side-by-side with any of them on Quantisnow.How can I track MGRX on Quantisnow?
Quantisnow aggregates Mangoceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MGRX to receive live email and push alerts on every new disclosure.